Health Care Up, but Not by Much, on Rotation Back to Tech - Health Care Roundup

Dow Jones06-12

Health-care companies rose, but not by as much as the broad market, as traders rotated back into the tech sector.

Novo Nordisk said its Wegovy weight-loss pill received commercial approval in the U.K., marking the first green light in Europe for the oral version of the drug. Shares of the Danish drug maker rose, but remain deep in the red for the year to date, as it struggles to keep up with demand and lofty Wall Street expectations and copes with intensifying generic and branded competition in the anti-obesity category.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

June 11, 2026 17:08 ET (21:08 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642523253?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-12 05:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642523253","market":"nz","top_or_hot":-1,"title":"Health Care Up, but Not by Much, on Rotation Back to Tech - Health Care Roundup","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Health-care companies rose, but not by as much as the broad market, as traders rotated back into the tech sector. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> said its Wegovy weight-loss pill received commercial approval in the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>., marking the first green light in Europe for the oral version of the drug. Shares of the Danish drug maker rose, but remain deep in the red for the year to date, as it struggles to keep up with demand and lofty Wall Street expectations and copes with intensifying generic and branded competition in the anti-obesity category. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 11, 2026 17:08 ET (21:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Health Care Up, but Not by Much, on Rotation Back to Tech - Health Care Roundup</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHealth Care Up, but Not by Much, on Rotation Back to Tech - Health Care Roundup\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-12 05:08</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Health-care companies rose, but not by as much as the broad market, as traders rotated back into the tech sector. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> said its Wegovy weight-loss pill received commercial approval in the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>., marking the first green light in Europe for the oral version of the drug. Shares of the Danish drug maker rose, but remain deep in the red for the year to date, as it struggles to keep up with demand and lofty Wall Street expectations and copes with intensifying generic and branded competition in the anti-obesity category. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 11, 2026 17:08 ET (21:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2642523253","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642523253","pubTimestamp":1781212080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Health-care companies rose, but not by as much as the broad market, as traders rotated back into the tech sector.Novo Nordisk said its Wegovy weight-loss pill received commercial approval in the U.K., marking the first green light in Europe for the oral version of the drug. Shares of the Danish drug maker rose, but remain deep in the red for the year to date, as it struggles to keep up with demand and lofty Wall Street expectations and copes with intensifying generic and branded competition in the anti-obesity category.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","XBI":"SPDR S&P Biotech ETF","BK4585":"ETF&股票定投概念","XLV":"健康照护类股ETF-SPDR","BK4581":"高盛持仓","LABU":"三倍做多标普生物-Direxion"},"translate_title":"医疗保健在回归科技的轮换中有所上升，但幅度不大——医疗保健综述","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBI":0.6,"XLV":1.5,"LABU":0.6},"content_text":"Health-care companies rose, but not by as much as the broad market, as traders rotated back into the tech sector. \n\n\nNovo Nordisk said its Wegovy weight-loss pill received commercial approval in the U.K., marking the first green light in Europe for the oral version of the drug. Shares of the Danish drug maker rose, but remain deep in the red for the year to date, as it struggles to keep up with demand and lofty Wall Street expectations and copes with intensifying generic and branded competition in the anti-obesity category. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n  (END) Dow Jones Newswires\n\n\n  June 11, 2026 17:08 ET (21:08 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642523253","isCrawlerRequest":true}